Respiratory Syncytial Virus and US Pediatric Intensive Care Utilization
2024

Impact of RSV on Pediatric ICU Utilization

Sample size: 119782 publication Evidence: moderate

Author Information

Author(s): Shanklin Alice MD, Olson Taylor MD, Patel Anita K. MD, Trujillo Rivera Eduardo A. PhD, Pollack Murray M. MD

Primary Institution: Children’s National Hospital

Hypothesis

What proportion of pediatric intensive care unit (ICU) admissions are associated with respiratory syncytial virus (RSV) infections, and could nirsevimab and the maternal RSVpreF vaccine be associated with pediatric intensive care utilization?

Conclusion

The study suggests that nirsevimab and the maternal RSVpreF vaccine could reduce pediatric ICU utilization.

Supporting Evidence

  • 11.4% of pediatric ICU encounters had RSV.
  • 38.6% of RSV cases were eligible for prevention.
  • RSV accounted for 21.1% of ICU days.
  • 65,757 encounters (54.9%) were male.
  • Median ICU length of stay was 1.8 days.

Takeaway

This study looked at how many kids go to the ICU because of a virus called RSV and found that new vaccines could help keep kids out of the ICU.

Methodology

This was a retrospective cross-sectional study examining US pediatric ICU encounters with and without RSV from January 1, 2017, to June 1, 2023.

Potential Biases

Potential underestimation of RSV impact due to missed infections and not accounting for RSV in neonatal ICUs.

Limitations

The study's efficacy estimates were based on early studies, and it could not determine if RSV was the primary reason for admission.

Participant Demographics

The median age was 4.5 years, with 54.9% male and 48.6% having public insurance.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1001/jamanetworkopen.2024.40997

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication